Zhou XM, Wu C, Gu X. Intravesically instilled gemcitabine-induced lung injury in a patient with invasive urothelial carcinoma: A case report. World J Clin Cases 2020; 8(19): 4652-4659 [PMID: 33083430 DOI: 10.12998/wjcc.v8.i19.4652]
Corresponding Author of This Article
Xiu Gu, MD, Doctor, Professor, Department of Respiratory and Critical Care Medicine, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Shenyang 110004, Liaoning Province, China. guxiu1968@126.com
Research Domain of This Article
Pharmacology & Pharmacy
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Oct 6, 2020; 8(19): 4652-4659 Published online Oct 6, 2020. doi: 10.12998/wjcc.v8.i19.4652
Intravesically instilled gemcitabine-induced lung injury in a patient with invasive urothelial carcinoma: A case report
Xiao-Ming Zhou, Cen Wu, Xiu Gu
Xiao-Ming Zhou, Xiu Gu, Department of Respiratory and Critical Care Medicine, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China
Xiao-Ming Zhou, Xiu Gu, Department of Respiratory and Critical Care Medicine, Fourth Hospital of China Medical University, Shenyang 110004, Liaoning Province, China
Cen Wu, Department of Pulmonary and Critical Care Medicine, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China
Author contributions: Zhou XM, Wu C, and Gu X were responsible for the diagnosis and treatment of the patient; Zhou XM contributed to the data collection and patient follow-up and wrote the manuscript; all authors have read and approved the final manuscript.
Informed consent statement: The patient has given the informed consent for the case report in this manuscript.
Conflict-of-interest statement: The authors have no conflicts of interest relevant to this article to disclose.
CARE Checklist (2016) statement: The manuscript has been checked according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Xiu Gu, MD, Doctor, Professor, Department of Respiratory and Critical Care Medicine, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Shenyang 110004, Liaoning Province, China. guxiu1968@126.com
Received: April 15, 2020 Peer-review started: April 15, 2020 First decision: July 25, 2020 Revised: July 28, 2020 Accepted: August 25, 2020 Article in press: August 25, 2020 Published online: October 6, 2020
Core Tip
Core Tip: Gemcitabine-induced pulmonary toxicities are rare and various, ranging from self-limited episodes of bronchospasm to fatal, progressive, severe, interstitial pneumonitis and respiratory failure. Intravesical gemcitabine instillations are commonly used to reduce recurrence or progression for non–muscle-invasive bladder cancer or urothelial cancer. Few severe toxicities have been reported for the intravesical instillation is assumed to be completely separate from the systemic circulation. In spite of the rare pulmonary involvement by the intravesical gemcitabine instillation, health care professionals who administer gemcitabine chemotherapy in this way should monitor for gemcitabine-induced pulmonary toxicities, particularly in patients with high-risk factors.
